Next was a series of talks by Rohini Pande on the economics of gender norms at home, at work, and in government at @econometric.bsky.social
Session 1: www.youtube.com/watch?v=VmA2...
Session 2 and 3: www.youtube.com/watch?v=nCFb...
Session 1: www.youtube.com/watch?v=VmA2...
Session 2 and 3: www.youtube.com/watch?v=nCFb...
EEA-ESEM 2026 | Lewis-Ostrom Lecture Series I by Rohini Pande (Yale University)
YouTube video by The Econometric Society
www.youtube.com
September 25, 2026 at 2:25 AM
Next was a series of talks by Rohini Pande on the economics of gender norms at home, at work, and in government at @econometric.bsky.social
Session 1: www.youtube.com/watch?v=VmA2...
Session 2 and 3: www.youtube.com/watch?v=nCFb...
Session 1: www.youtube.com/watch?v=VmA2...
Session 2 and 3: www.youtube.com/watch?v=nCFb...
先日塗装失敗したデミトレをドボンして仕上げ直しました(^q^)
今度はオーバーコートにDSPIAEの水性プレミックス塗料のグロスクリアーを使ってみましたがとても良かった
【完成報告】デミトレーナー支援装備型｜まサる(msr457) note.com/rrtac/n/ncfb...
今度はオーバーコートにDSPIAEの水性プレミックス塗料のグロスクリアーを使ってみましたがとても良かった
【完成報告】デミトレーナー支援装備型｜まサる(msr457) note.com/rrtac/n/ncfb...
【完成報告】デミトレーナー支援装備型｜まサる(msr457)
以前に塗装の一部溶け出しで完成（失敗）報告となってしまったデミトレ2号機、なんだかんだやはり気になりドボンして塗装し直して改めて完成報告となります。
とりあえず完成写真を一通り。 本来想定した完成品となって喉に引っかかってた小骨が取れた感じです。 仕上げ直しで一番面倒だなと感じてたのがデカールの貼り直しだったんですが数えてみて30枚程度だったのでそれほどの数でもないのかと思った感じですね。...
note.com
May 22, 2026 at 2:59 PM
先日塗装失敗したデミトレをドボンして仕上げ直しました(^q^)
今度はオーバーコートにDSPIAEの水性プレミックス塗料のグロスクリアーを使ってみましたがとても良かった
【完成報告】デミトレーナー支援装備型｜まサる(msr457) note.com/rrtac/n/ncfb...
今度はオーバーコートにDSPIAEの水性プレミックス塗料のグロスクリアーを使ってみましたがとても良かった
【完成報告】デミトレーナー支援装備型｜まサる(msr457) note.com/rrtac/n/ncfb...
This #CME podcast is designed for pulmonologists who are involved in the management of patients with non-cystic fibrosis bronchiectasis.
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/ncfb?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/ncfb?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
July 18, 2026 at 6:25 PM
This #CME podcast is designed for pulmonologists who are involved in the management of patients with non-cystic fibrosis bronchiectasis.
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/ncfb?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/ncfb?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
Earn #CME credit with this podcast episode, "NCFB: Patient Selection and Comprehensive Care."
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/pulmonology/20260313/4ncfb-patient-selection-and-comprehensive-care/overview?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/pulmonology/20260313/4ncfb-patient-selection-and-comprehensive-care/overview?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
July 1, 2026 at 3:45 PM
Earn #CME credit with this podcast episode, "NCFB: Patient Selection and Comprehensive Care."
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/pulmonology/20260313/4ncfb-patient-selection-and-comprehensive-care/overview?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/pulmonology/20260313/4ncfb-patient-selection-and-comprehensive-care/overview?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
In this #CME podcast, experts discuss key clinical trial data that guides evidence-based management for patients with non-cystic fibrosis bronchiectasis.
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/pulmonology/20260313/3the-evidence-for-ddp1-inhibition-in-ncfb
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/pulmonology/20260313/3the-evidence-for-ddp1-inhibition-in-ncfb
June 25, 2026 at 3:29 PM
In this #CME podcast, experts discuss key clinical trial data that guides evidence-based management for patients with non-cystic fibrosis bronchiectasis.
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/pulmonology/20260313/3the-evidence-for-ddp1-inhibition-in-ncfb
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/pulmonology/20260313/3the-evidence-for-ddp1-inhibition-in-ncfb
Earn #CME credit with this podcast series, "Beyond the Airways: Progress in Non-Cystic Fibrosis Bronchiectasis Care" available on MedEd Talks: https://www.healio.com/cme/mededtalks/ncfb?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
June 5, 2026 at 3:01 PM
Earn #CME credit with this podcast series, "Beyond the Airways: Progress in Non-Cystic Fibrosis Bronchiectasis Care" available on MedEd Talks: https://www.healio.com/cme/mededtalks/ncfb?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
Earn #CME credit with this podcast episode, "The Evidence for DDP-1 Inhibition in NCFB."
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/pulmonology/20260313/3the-evidence-for-ddp1-inhibition-in-ncfb?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/pulmonology/20260313/3the-evidence-for-ddp1-inhibition-in-ncfb?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
May 19, 2026 at 6:01 PM
Earn #CME credit with this podcast episode, "The Evidence for DDP-1 Inhibition in NCFB."
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/pulmonology/20260313/3the-evidence-for-ddp1-inhibition-in-ncfb?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/pulmonology/20260313/3the-evidence-for-ddp1-inhibition-in-ncfb?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
Listen to this podcast to learn more about the role of neutrophilic inflammation and mucus dysfunction in non-cystic fibrosis bronchiectasis: https://www.healio.com/cme/mededtalks/pulmonology/20260313/2how-dpp1-works-in-ncfb?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
#CME
#CME
May 8, 2026 at 12:01 PM
Listen to this podcast to learn more about the role of neutrophilic inflammation and mucus dysfunction in non-cystic fibrosis bronchiectasis: https://www.healio.com/cme/mededtalks/pulmonology/20260313/2how-dpp1-works-in-ncfb?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
#CME
#CME
In this 4-part #CME podcast series, Dr. Charles L. Daley is joined by expert faculty to evaluate strategies for appropriate patient selection and multidisciplinary care in patients with non-cystic fibrosis bronchiectasis.
Find it here: https://www.healio.com/cme/mededtalks/ncfb
Find it here: https://www.healio.com/cme/mededtalks/ncfb
April 26, 2026 at 1:01 PM
In this 4-part #CME podcast series, Dr. Charles L. Daley is joined by expert faculty to evaluate strategies for appropriate patient selection and multidisciplinary care in patients with non-cystic fibrosis bronchiectasis.
Find it here: https://www.healio.com/cme/mededtalks/ncfb
Find it here: https://www.healio.com/cme/mededtalks/ncfb
Listen to this podcast for key clinical trial data that guides evidence-based management for patients with non-cystic fibrosis bronchiectasis: https://www.healio.com/cme/mededtalks/pulmonology/20260313/3the-evidence-for-ddp1-inhibition-in-ncfb
#CME
#CME
April 16, 2026 at 8:01 PM
Listen to this podcast for key clinical trial data that guides evidence-based management for patients with non-cystic fibrosis bronchiectasis: https://www.healio.com/cme/mededtalks/pulmonology/20260313/3the-evidence-for-ddp1-inhibition-in-ncfb
#CME
#CME
Earn #CME credit with this podcast episode, "How DPP-1 Works in NCFB."
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/pulmonology/20260313/2how-dpp1-works-in-ncfb?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/pulmonology/20260313/2how-dpp1-works-in-ncfb?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
April 8, 2026 at 9:30 PM
Earn #CME credit with this podcast episode, "How DPP-1 Works in NCFB."
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/pulmonology/20260313/2how-dpp1-works-in-ncfb?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
Available on MedEd Talks: https://www.healio.com/cme/mededtalks/pulmonology/20260313/2how-dpp1-works-in-ncfb?utm_source=bluesky&utm_medium=Post&utm_campaign=H622
Non-cystic fibrosis bronchiectasis is a chronic inflammatory airway disease characterized by abnormal bronchial dilation, mucus retention, recurrent infections, and progressive lung damage.
Listen to this podcast series that explores progress in care: https://www.healio.com/cme/mededtalks/ncfb
Listen to this podcast series that explores progress in care: https://www.healio.com/cme/mededtalks/ncfb
March 30, 2026 at 2:06 PM
Non-cystic fibrosis bronchiectasis is a chronic inflammatory airway disease characterized by abnormal bronchial dilation, mucus retention, recurrent infections, and progressive lung damage.
Listen to this podcast series that explores progress in care: https://www.healio.com/cme/mededtalks/ncfb
Listen to this podcast series that explores progress in care: https://www.healio.com/cme/mededtalks/ncfb
Neutrophilic inflammation, amplified by dysregulated cytokine responses, possibly sustained by microbial dysbiosis, appears central to paediatric NCFB. Key gaps include roles of dysbiosis, adaptive immunity, immune trajectories and lesser-known pathways. https://bit.ly/4aW3xsP
Bronchiectasis in children: a systematic review of cytokine profile, immune cell phenotypes and microbiota in bronchoalveolar lavage fluid
BackgroundPaediatric noncystic fibrosis bronchiectasis (NCFB) is a chronic respiratory condition characterised by airway infection, chronic inflammation, mucociliary dysfunction and structural lung damage. Emerging evidence highlights the importance of ...
bit.ly
February 28, 2026 at 1:34 PM
Neutrophilic inflammation, amplified by dysregulated cytokine responses, possibly sustained by microbial dysbiosis, appears central to paediatric NCFB. Key gaps include roles of dysbiosis, adaptive immunity, immune trajectories and lesser-known pathways. https://bit.ly/4aW3xsP
ERJ Open Research: ETI therapy in patients with NCFB and an amenable CFTR mutation led to a significant improvement in pulmonary function, clinical status and daily symptoms, suggesting ETI may prove beneficial as an adjuvant therapy for NCFB https://bit.ly/3DVXiIQ
November 11, 2025 at 2:47 PM
ERJ Open Research: ETI therapy in patients with NCFB and an amenable CFTR mutation led to a significant improvement in pulmonary function, clinical status and daily symptoms, suggesting ETI may prove beneficial as an adjuvant therapy for NCFB https://bit.ly/3DVXiIQ
Today on A Public Affair, @thetallnathan.bsky.social of the NCFB, Karl Habeck of WOJB, and Jessie Dick of WXPR discuss the impact of CPD funding cuts on community radio.
Listen Here: www.wortfm.org/the-impact-o...
Listen Here: www.wortfm.org/the-impact-o...
The Impact of CPD Funding on Community Radio - WORT-FM 89.9
Last week, Trump signed a bill to cut federal funding to the Corporation of Public Broadcasting (CPB) over $1.1 billion dollars. Community radio managers discuss how their local communities will be af...
www.wortfm.org
July 28, 2025 at 7:49 PM
Today on A Public Affair, @thetallnathan.bsky.social of the NCFB, Karl Habeck of WOJB, and Jessie Dick of WXPR discuss the impact of CPD funding cuts on community radio.
Listen Here: www.wortfm.org/the-impact-o...
Listen Here: www.wortfm.org/the-impact-o...
$INSM +6.3% [BRINSUPRI, the first & only FDA-approved oral treatment for Non-Cystic Fibrosis Bronchiectasis (NCFB), is available for adults/children 12+. This first-in-class DPP1 inhibitor reduces exacerbations for ~500k US patients. Available by prescription.] investor.insmed.com/2025-08-12-F...
August 12, 2025 at 5:22 PM
$INSM +6.3% [BRINSUPRI, the first & only FDA-approved oral treatment for Non-Cystic Fibrosis Bronchiectasis (NCFB), is available for adults/children 12+. This first-in-class DPP1 inhibitor reduces exacerbations for ~500k US patients. Available by prescription.] investor.insmed.com/2025-08-12-F...
Non-Cystic Fibrosis Bronchiectasis (NCFB) Market is Projected to Witness Robust Growth by 2036 Owing to the Launch of First-in-Class Disease-Modifying Therapies and Expanding Bronchiectasis Treatment
Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Is Projected To Witness Robust Growth By 2036 Owing To The Launch Of First-in-Class Disease-Modifying Therapies And Expanding Bronchiectasis Treatment | PressReleaseCC
DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Non-Cystic Fibrosis Bronchiectasis (NCFB) Market
www.pressreleasecc.com
July 8, 2026 at 2:12 AM
Non-Cystic Fibrosis Bronchiectasis (NCFB) Market is Projected to Witness Robust Growth by 2036 Owing to the Launch of First-in-Class Disease-Modifying Therapies and Expanding Bronchiectasis Treatment
Step one would be to have functional insurance and utility commissions. When I complained about unjustified NCFB increases I was literally told by GOP commissioner, "they can do whatever they want as long as it is across the board". NO. That's NOT what your job is!
March 19, 2026 at 8:07 PM
Step one would be to have functional insurance and utility commissions. When I complained about unjustified NCFB increases I was literally told by GOP commissioner, "they can do whatever they want as long as it is across the board". NO. That's NOT what your job is!
